ClinicalTrials.gg
CompletedNCT06449183Updated Mar 6, 2026

VIDAS® TBI Real Life Performance in Subjects With Mild Traumatic Brain Injury (mTBI)

An interventional study of VIDAS® TBI Test [GFAP and UCH-L1 assays] in Mild Traumatic Brain Injury, sponsored by BioMérieux. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by BioMérieux · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
903
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 420 studies in Brain Concussion with a site in United States — 102 open to participants now, 123 under way, 5 of them phase 3. Brain Concussion · United States.

Enrollment
10th of 323
903 · median 60
Started
2024
with 27 others
No phase
265 of 420
63 open now
Registered
356th of 420
by date

Among the 420 studies in Brain Concussion with a site in United States, this one is the 10th largest by enrollment of the 323 interventional ones that give a count, is one of 28 that started in 2024, is one of 265 with no phase, and was the 356th registered.

Brain Concussion

641 studies on the registry are indexed under Brain Concussion; 167 are open to participants now.

Browse Brain Concussion studies →

Open to participants now

102 of the 420 studies in Brain Concussion with a site in United States are open now. Recruiting first, the newest first:

97 more — sign in →

All 102 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 114 Brain Concussion studies recruiting now, 34 (30%) set no upper age limit and 73 (64%) stop at 75 or younger; 24 take children under 18; 38 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 420 studies in Brain Concussion with a site in United States, or all of them as a file.
02

Study summary

Decision Rules for an initial CT-scan in patients arriving to Emergency Department (ED) and presenting a mild traumatic brain injury could be optimized by the use of an objective parameter easily and rapidly measured. This may be the place for serum biomarkers providing a quick and accurate assessment. BioMérieux has now developed an automated assay for the measurement of serum Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase (UCH-L1), the VIDAS® TBI assay to fill out this unmet needs. The goal of the herein study is to generate real-world data and evidences to support the VIDAS® TBI performances.

Read the detailed description

The assessment of severity of TBI patients is based on the Glasgow Coma Scale (GCS) and the initial management in the ED includes performing a non-contrast brain Computed Tomography (CT) scan if the patient meets specific conditions. To date, real world data show that EDs would actually not follow guideline recommendations and a substantial CT overuse is observed. Management strategies are becoming more and more focused on selective CT use to effectively manage health care resources. Efforts have been made to optimize the indications for brain CT scan after mTBI. Although brain CT scan plays a central role after mTBI, there is an unmet clinical need for an objective tool to optimize indications for CT scan, reduce patient radiation exposure, and possibly predict patient outcome. Clinical Decision Rules for an initial CT-scan could be optimized by the use of an objective parameter easily and rapidly measured. This may be the place for serum biomarkers providing a quick and accurate assessment. BioMérieux has now developed an automated assay for the measurement of serum Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase (UCH-L1), the VIDAS® TBI assay to fill out this unmet needs. The goal of the herein study is to generate real-world data and evidences to support the VIDAS® TBI performances.

03

Conditions studied

  • Mild Traumatic Brain Injury

Keywords

  • Mild Traumatic Brain Injury
  • mTBI
  • TBI
  • Biomarkers
  • Automated assays
  • Ubiquitin Carboxy-terminal Hydrolase-L1 (UCH-L1)
  • Glial Fibrillary Acidic Protein (GFAP)
  • Canadian CT Head Rule
  • Canadian CT Head Rule (CCHR)
  • Performance
  • Economic outcomes
  • Clinical outcomes
  • CT-Scan
  • Emergency Department (ED)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subject ≥ 18 years old
  • Subject with a Glasgow Coma Scale (GCS) score between 13-15 on admission
  • Subject presenting to the Emergency Department for suspected mild Traumatic Brain Injury
  • Subject with a non-contrast head Computed Tomography (CT) scan ordered per the clinical site's care usual care
  • Blood sampling possible within 12 hours of injury (1 tube of 4-5 mL of blood)
  • Subject expected to stay at least 2 hours in the ED or in a ward
  • Subject with signed Form (ICF)

Exclusion criteria

Exclusion Criteria:

  • Time of injury unknown
  • Subject with non-traumatic neurological disorders (e.g, dementia, Parkinson's disease, multiple sclerosis, seizure disorder, brain tumors, spontaneous intracranial haematoma)
  • Neurosurgery, stroke or within the last 30 days
  • Subject with an active cancer
  • Subject with penetrating head injury
  • Special populations, including women with known pregnancy, prisoners, or institutionalized individuals
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
903 participants (actual)

Study arms

  • Experimental
    Subjects with Mild Traumatic Brain injury

    Subjects presenting to the ED within 12 hours of suspected mild head trauma and a Glasgow Score of 13-15 undergo to blood collection for VIDAS® TBI \[GFAP, UCH-L1\] testing.

    Diagnostic Test: VIDAS® TBI Test [GFAP and UCH-L1 assays]

Interventions

  • Diagnostic testVIDAS® TBI Test [GFAP and UCH-L1 assays]

    The VIDAS® TBI (GFAP, UCH-L1) test is composed of two automated assays - VIDAS® TBI (GFAP) and VIDAS® TBI (UCH-L1) - to be used on the VIDAS® family of instruments for the quantitative measurement of Glial 15 Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase- L1 (UCH-L1) in human serum using the Enzyme Linked Fluorescent Assay (ELFA) technique. The results of both assays are required to obtain an overall qualitative test interpretation.

06

What researchers measure

Primary outcomes

  1. To determine VIDAS® TBI sensitivity to exclude the presence of an intracranial lesion

    Time frame: 12 hours post mild brain trauma

  2. To determine VIDAS® TBI specificity to exclude the presence of an intracranial lesion

    Time frame: 12 hours post mild brain trauma

  3. To determine VIDAS® TBI Positive Predictive Value to exclude the presence of an intracranial lesion

    Time frame: 12 hours post mild brain trauma

  4. To determine VIDAS® TBI Negative Predictive Value to exclude the presence of an intracranial lesion

    Time frame: 12 hours post mild brain trauma

  5. To determine VIDAS® TBI Positive Likelihood Ratio to exclude the presence of an intracranial lesion

    Time frame: 12 hours post mild brain trauma

  6. To assess VIDAS® TBI Negative Likelihood Ratio to exclude the presence of an intracranial lesion

    Time frame: 12 hours post mild brain trauma

Secondary outcomes

  1. To determine Canadian CT Head Rule specificity combined to VIDAS specificity to exclude the presence of an intracranial lesion

    Time frame: 12 hours post mild brain trauma

  2. To determine Canadian CT Head Rule sensitivity combined to VIDAS sensitivity to exclude the presence of an intracranial lesion

    Time frame: 12 hours post mild brain trauma

  3. To determine Canadian CT Head Rule Positive Predictive Value combined to VIDAS positive Predictive Value to exclude the presence of an intracranial lesion

    Time frame: 12 hours post mild brain trauma

  4. To determine Canadian CT Head Rule Negative Predictive Value combined to VIDAS Negative Predictive Value to exclude the presence of an intracranial lesion

    Time frame: 12 hours post mild brain trauma

  5. To determine Canadian CT Head Rule Negative Likelihood Ratio combined to VIDAS Negative Likelihood Ration to exclude the presence of an intracranial lesion

    Time frame: 12 hours post mild brain trauma

  6. To determine Canadian CT Head Rule Positive Likelihood Ratio combined to VIDAS Positive Likelihood Ration to exclude the presence of an intracranial lesion

    Time frame: 12 hours post mild brain trauma

  7. To estimate the impact of the use of VIDAS® TBI on the time to discharge

    Time frame: 3 months

  8. To estimate the expected impact of the use of VIDAS® TBI on patient stay in the ED

    Time frame: 3 months

  9. To estimate the expected impact of the use of VIDAS® TBI on hospitalization decision

    Time frame: 3 months

  10. To estimate the expected impact of the use of VIDAS® TBI on time to medical decision

    Time frame: 3 months

  11. To estimate the impact of the use of VIDAS® TBI on the patient's monitoring duration

    Time frame: 3 months

  12. to measure the percentage of CT-scan potentially avoided

    Time frame: 3 months

  13. To estimate the saving costs when using VIDAS® TBI in comparison with usual clinical sites' care.

    Time frame: 3 months

  14. To estimate the costs of Length of stay in Emergency Department (ED) when using VIDAS® TBI in comparison with usual clinical sites' care.

    Time frame: 3 months

  15. To estimate the associated costs of Length of stay in the hospital when using VIDAS® TBI in comparison with usual clinical sites' care.

    Time frame: 3 months

07

Study locations

5 sites
  • Orlando Health
    Orlando, Florida 32806, United States
  • Wayne State University
    Detroit, Michigan 48202, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University
    St Louis, Missouri 63130, United States
  • University of Rochester
    Rochester, New York 14627, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Sep 2025, 15 months.

Of 265 interventional studies with no phase under Brain Concussion, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2024
First posted
Jun 7, 2024
StartActual
May 16, 2024
Primary completionActual
Sep 3, 2025
CompletionActual
Nov 12, 2025
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06449183
Lead sponsor
BioMérieux
Responsible party
Sponsor
First posted
Jun 7, 2024
Start date
May 16, 2024
Primary completion
Sep 3, 2025
Completion
Nov 12, 2025
Last update
Mar 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion